Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44416   clinical trials with a EudraCT protocol, of which   7423   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

    Summary
    EudraCT number
    2009-013126-16
    Trial protocol
    GB   FR   ES   IT  
    Global end of trial date
    08 Apr 2026

    Results information
    Results version number
    v1(current)
    This version publication date
    18 Oct 2026
    First version publication date
    18 Oct 2026
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    TMC125-TIDP35-C239
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00980538
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Janssen-Cilag International NV
    Sponsor organisation address
    Turnhoutseweg 30, Beerse, Belgium, B-2340
    Public contact
    Clinical Registry Group, Janssen-Cilag International N.V., ClinicalTrialsEU@its.jnj.com
    Scientific contact
    Clinical Registry Group, Janssen-Cilag International N.V., ClinicalTrialsEU@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 Apr 2026
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Apr 2026
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The main objective of the trial was to continue the provision of Etravirine (ETR) for adult and pediatric subjects who previously received ETR in a clinical study sponsored by Janssen Research & Development (JRD), and who continued to benefit from the use of ETR, in countries where at the time parent trial closed, ETR was not commercially available for the subject’s indication, was not reimbursed, could not be accessed through another source (for example, access program or government program), or where the subject was not eligible for ongoing studies/programs with ETR. Trial was closed when last subject was switched to commercial available ETR or to other locally available Human Immunodeficiency Virus (HIV) treatment.
    Protection of trial subjects
    This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 Dec 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 11
    Country: Number of subjects enrolled
    Brazil: 8
    Country: Number of subjects enrolled
    Canada: 1
    Country: Number of subjects enrolled
    Spain: 7
    Country: Number of subjects enrolled
    France: 3
    Country: Number of subjects enrolled
    Italy: 6
    Country: Number of subjects enrolled
    Panama: 4
    Country: Number of subjects enrolled
    Romania: 1
    Country: Number of subjects enrolled
    Thailand: 12
    Country: Number of subjects enrolled
    United States: 5
    Country: Number of subjects enrolled
    South Africa: 122
    Worldwide total number of subjects
    180
    EEA total number of subjects
    17
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    27
    Adolescents (12-17 years)
    44
    Adults (18-64 years)
    106
    From 65 to 84 years
    3
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Total of 180 subjects who previously received etravirine (ETR) in a clinical trial with ETR (EudraCT numbers: 2005-003145-13,2006-001287-23,2006-001287-23,2007-007086-21,2012-002630-36) continued its use, in countries where at time parent clinical trial closed, ETR was not available, could not be accessed through any source were enrolled in study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded
    Blinding implementation details
    Not blinded

    Arms
    Arm title
    Etravirine
    Arm description
    Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use.
    Arm type
    Experimental

    Investigational medicinal product name
    Etravirine
    Investigational medicinal product code
    Other name
    TMC125
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Adult subjects received a dose of ETR 200 mg twice daily. Pediatric subjects received ETR, dosed as they had received in the previous ETR (parent) trial, with weight based dose adjustment if necessary (ETR 100 mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125 mg bid for weight 20 to <25 kg; ETR 150 mg bid for weight 25 to <30 kg; and 200 mg bid for weight greater than or equal to [>=] 30 kg).

    Number of subjects in period 1
    Etravirine
    Started
    180
    Completed
    180

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Etravirine
    Reporting group description
    Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use.

    Reporting group values
    Etravirine Total
    Number of subjects
    180 180
    Age categorical
    Units: Subjects
        In Utero
    0 0
        Preterm newborn infants (gestional age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days - 23 months)
    0 0
        Children (2 - 11 years)
    27 27
        12 - 17 years
    44 44
        Adults (18 - 64 years)
    106 106
        From 65 - 84 years
    3 3
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    30.9 ( 16.92 ) -
    Gender categorical
    Units: Subjects
        Male
    68 68
        Female
    112 112

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Etravirine
    Reporting group description
    Subjects who previously received etravirine(ETR) in clinical trial with ETR(2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20 kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to <30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use.

    Primary: Number of Subjects With at Least One Adverse Event as a Measure of Safety Through the Time Etravirine (ETR)-Based Treatment Regimen Became Commercially Available

    Close Top of page
    End point title
    Number of Subjects With at Least One Adverse Event as a Measure of Safety Through the Time Etravirine (ETR)-Based Treatment Regimen Became Commercially Available [1]
    End point description
    An adverse event is any untoward medical event that occurs in a subject administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Safety analysis set included all subjects who received at least one dose of etravirine.
    End point type
    Primary
    End point timeframe
    Up to 10 years 11 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be reported for this endpoint.
    End point values
    Etravirine
    Number of subjects analysed
    180
    Units: Subjects
    42
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Up to 10 years 11 months
    Adverse event reporting additional description
    Safety analysis set included all subjects who received at least one dose of etravirine.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23.0
    Reporting groups
    Reporting group title
    Etravirine
    Reporting group description
    Subjects who previously received etravirine(ETR) in a clinical trial with ETR (2005-003145-13, 2006-001287-23, 2006-001287-23, 2007-007086-21, 2012-002630-36) sponsored by/in collaboration with Janssen Research & Development, continued to benefit from its use, in countries where ETR was not available, could not be accessed through another source, or where subject was not eligible for ongoing trials with ETR received ETR 200milligrams (mg) twice daily (bid) in adults. Pediatric subjects received ETR doses as received in previous ETR (parent) trial, with weight based dose adjustment if necessary(ETR 100mg twice daily for weight 10 to less than [<] 20kilograms [kg]; ETR 125mg bid for weight 20 to <25kg; ETR 150mg bid for weight 25 to<30kg; and 200mg bid for weight greater than or equal to [>=] 30kg). Treatment continued until one of following criteria was met: subject no longer benefited from ETR treatment, toxicity, loss to follow up, ETR became commercially available for subject's use.

    Serious adverse events
    Etravirine
    Total subjects affected by serious adverse events
         subjects affected / exposed
    18 / 180 (10.00%)
         number of deaths (all causes)
    6
         number of deaths resulting from adverse events
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Metastases to Lymph Nodes
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metastases to Central Nervous System
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Melanoma Recurrent
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Malignant Melanoma
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Brain Herniation
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Radius Fracture
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Limb Injury
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Head Injury
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Hypovolaemic Shock
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Myocardial Infarction
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Pregnancy, puerperium and perinatal conditions
    Abortion Spontaneous
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Encephalopathy
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Death
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Accidental Death
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Skin and subcutaneous tissue disorders
    Angioedema
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Acute Kidney Injury
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Psychiatric disorders
    Depression
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    Infections and infestations
    Chronic Tonsillitis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Disseminated Tuberculosis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypovolaemia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Hyponatraemia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Etravirine
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    32 / 180 (17.78%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Skin Papilloma
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Pregnancy, puerperium and perinatal conditions
    Pregnancy
         subjects affected / exposed
    4 / 180 (2.22%)
         occurrences all number
    4
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    3
    Reproductive system and breast disorders
    Amenorrhoea
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    2
    Respiratory, thoracic and mediastinal disorders
    Nasal Congestion
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Cough
         subjects affected / exposed
    5 / 180 (2.78%)
         occurrences all number
    7
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Investigations
    Lipase Increased
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Hepatic Enzyme Increased
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Injury, poisoning and procedural complications
    Ligament Sprain
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Cardiac disorders
    Mitral Valve Incompetence
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Sinus Tachycardia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Neuropathy Peripheral
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Headache
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    2
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Thrombocytopenia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    2
    Eye disorders
    Conjunctival Haemorrhage
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Odynophagia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Abdominal Pain
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Abdominal Pain Upper
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Diarrhoea
         subjects affected / exposed
    3 / 180 (1.67%)
         occurrences all number
    4
    Aphthous Ulcer
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    4 / 180 (2.22%)
         occurrences all number
    4
    Prurigo
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Neurodermatitis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Lipohypertrophy
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Lipoatrophy
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Acne
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Skin Hypopigmentation
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Renal and urinary disorders
    Nephropathy
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Back Pain
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Pain in Extremity
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    2
    Infections and infestations
    Conjunctivitis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Gastroenteritis
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    2
    Gastroenteritis Viral
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Tonsillitis
         subjects affected / exposed
    4 / 180 (2.22%)
         occurrences all number
    5
    Respiratory Tract Infection
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Otitis Media
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    2
    Oral Herpes
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    2
    Nasopharyngitis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Lower Respiratory Tract Infection
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Lice Infestation
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Influenza
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Herpes Simplex
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Tracheobronchitis
         subjects affected / exposed
    1 / 180 (0.56%)
         occurrences all number
    1
    Upper Respiratory Tract Infection
         subjects affected / exposed
    5 / 180 (2.78%)
         occurrences all number
    6
    Vulvovaginal Candidiasis
         subjects affected / exposed
    2 / 180 (1.11%)
         occurrences all number
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 21 06:11:04 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA